Aethlon Medical(US:AEMD)2025-11-12 22:10Financial Performance - Consolidated operating expenses for Q3 2025 were approximately $1,510,000, a decrease of $1,392,000 or 48% compared to $2,902,000 in Q3 2024[101] - Net loss for Q3 2025 decreased to $1,487,100 from $2,806,973 in Q3 2024, with basic and diluted loss per share improving from ($16.11) to ($3.74)[106] - For the six months ended September 30, 2025, operating expenses were approximately $3,302,000, down $2,220,000 or 40% from $5,522,000 in the same period of 2024[107] - Comprehensive loss for the six months ended September 30, 2025, was $3,258,202, compared to $5,375,443 for the same period in 2024[111] - Net cash used in operating activities was approximately $3,374,000 for the six months ended September 30, 2025, a decrease from approximately $3,962,000 for the same period in 2024[116] - Net cash provided by financing activities decreased by approximately $1,640,000 for the six months ended September 30, 2025, raising $3,744,000 compared to $5,384,000 in the same period of 2024[117] - Future capital requirements will depend on various factors, with expectations of continued negative cash flows and net losses for the foreseeable future[119] Cash and Inventory - Cash balance as of September 30, 2025, was $5,853,493, an increase from $5,501,261 at March 31, 2025[112] - The company has sufficient inventory of Hemopurifiers to support ongoing trials in Australia[95] Clinical Trials and Product Development - The Hemopurifier has been used safely in 167 sessions with 41 patients, demonstrating potential to remove enveloped viruses[86] - Enrollment for Cohort 2 of the oncology trial is open, aiming to enroll approximately 9 to 18 patients[88] - The company is exploring new applications for the Hemopurifier, with a study showing >98% removal of platelet-derived extracellular vesicles[92] - Clinical trial expenses for the planned oncology trial in Australia are expected to increase for the foreseeable future, including costs for manufacturing additional Hemopurifiers[118] Economic and Market Conditions - The company is monitoring the impact of inflation and geopolitical events on its business and future access to capital[97] - The ability to raise additional funds may be adversely impacted by worsening global economic conditions and market volatility[121] - The company plans to access equity markets for additional capital, but there is no assurance of favorable terms[120] Accounting Policies - Critical accounting estimates include long-lived assets, stock-based compensation, and clinical trial accruals, which are essential for portraying financial condition[123] - There have been no changes to critical accounting policies and estimates since the Annual Report for the year ended March 31, 2025[124]